SFBN Feed: Cellipont Bioservices and Xiogenix Announce Strategic Partnership to Enhance Client Access to Advanced Filling Systems https://lnkd.in/gmMpn54d THE WOODLANDS, Texas and MUSKEGO, Wis., Dec. 10, 2024 /PRNewswire/ — Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in biopharmaceutical technology, are pleased to announce a [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
San Francisco Biotech Networks的动态
最相关的动态
-
Want to know more about Sphere Fluidics Limited and the role of picodroplet technology in biologics discovery? Sign up for our webinar on 4th December to hear our CTO, Richard Hammond, discuss how this approach could revolutionize your work-flow. #CellLineDevelopment #Microfluidics #Automation
?? New Webinar Alert! ?? Join us on Wednesday, December 4th for an insightful presentation by Richard Hammond on: "Picodroplets for Biologics Discovery and Scale-up: A Novel Automation Approach," hosted by Pharmaceutical Technology. ?? Date: December 4, 2024 ? Time: 11:00 AM EST ?? Sign up here https://bit.ly/4flTluF What you’ll gain: ? Discover the power of picodroplets for single-cell analysis ? Learn how the Cyto-Mine? Chroma enhances biologics discovery and scale-up ? Explore the latest advances in multiplex measurements Event Overview: Ultraminiaturized droplet microfluidics is revolutionizing biologics discovery. In this webinar, Richard Hammond will discuss the innovative integration of picodroplet technology into automated systems, showcasing its role in advancing translational research. Real-world examples and exciting new capabilities will be presented—don’t miss it! #BioTech #Microfluidics #CellLineDevelopment
-
-
Dive into Pharma's Almanac roundtable for insights from leading experts at companies like Lonza, Samsung Biologics, and Thermo Fisher Scientific. Discover how the pharmaceutical industry is harnessing fresh ideas from adjacent sectors to boost drug development!?
?? ???????? ?????? ????????????????????????: ?????? ???? ?????? ???????????? ???????????????? ?????????????????????? ?????????????????????? ???????? ???????????????? ???????????????????? ???? ?????????????? ???????? ??????????????????????? ?? Curious about how the pharmaceutical industry is evolving with insights from other sectors? In this Pharma's Almanac roundtable, a panel of industry experts share their insights on latest innovations shaping the biopharma sector. ?? ???????? ?????? ???????????????????? ????????: https://lnkd.in/e4Z_acjV Our roundtable features contributors from: Kosten Digital, Lonza, Likarda, Germfree, ScaleReady, Gelteq, Lifecore Biomedical, Refeyn, Navin Molecular, Samsung Biologics, Elixirgen Therapeutics, Inc., Quotient Therapeutics, Cytiva, Empress Therapeutics, Thermo Fisher Scientific, LabVantage Solutions, Inc, SciY, Roquette, ACD, and Bruker BioSpin. #PharmaInnovation #DrugDevelopment #PharmaceuticalIndustry #Roundtable #CDMO
-
-
Global Biopharmaceuticals and Biotechnology Equity Research Analyst Vamil Divan, MD, MBA joins CNBC to discuss the initial 2025 guidance presented by a leading global biopharmaceutical company and why he's optimistic about the various therapeutics in the company's product pipeline. Watch his segment: https://lnkd.in/ev9CwYWc Learn more about Guggenheim Securities Healthcare Research: https://lnkd.in/eSgTkerH
-
-
Editor in Chief, Partner, Pharma's Almanac, and Chief Science Officer, Partner, That's Nice
Discover how cross-industry innovations are transforming drug development in pharma—check out Pharma's Almanac roundtable with insights from industry leaders! ??
?? ???????? ?????? ????????????????????????: ?????? ???? ?????? ???????????? ???????????????? ?????????????????????? ?????????????????????? ???????? ???????????????? ???????????????????? ???? ?????????????? ???????? ??????????????????????? ?? Curious about how the pharmaceutical industry is evolving with insights from other sectors? In this Pharma's Almanac roundtable, a panel of industry experts share their insights on latest innovations shaping the biopharma sector. ?? ???????? ?????? ???????????????????? ????????: https://lnkd.in/e4Z_acjV Our roundtable features contributors from: Kosten Digital, Lonza, Likarda, Germfree, ScaleReady, Gelteq, Lifecore Biomedical, Refeyn, Navin Molecular, Samsung Biologics, Elixirgen Therapeutics, Inc., Quotient Therapeutics, Cytiva, Empress Therapeutics, Thermo Fisher Scientific, LabVantage Solutions, Inc, SciY, Roquette, ACD, and Bruker BioSpin. #PharmaInnovation #DrugDevelopment #PharmaceuticalIndustry #Roundtable #CDMO
-
-
I like this configuration.
???????? ?????????????? ?????????????????? ?? More than 400 companies, broken down into 3 main areas of regenerative medicine. - Small Molecule - Biologics - CGT #pharma #biotech #cdmo #biopharma
-
-
Speed to first-in-human studies for biologics requires the right expertise and technology to ensure successful development and manufacturing scale up. View this on-demand webinar introducing GPEx? Lightning: a fast, flexible & tailored process for generating highly stable & productive mammalian cell lines. https://ow.ly/apfI50R5Wvy
Leveraging Proven Technology to Speed Path to First-In-Human Studies with GPEx? Lightning
https://biologics.catalent.com
-
Thoughts on this? >> Gilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #pharmaceutical #healthcare
Gilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug
endpts.com
-
By deferring traditional single cell cloning to later stages of development and leveraging stable bulk cultures (SBCs) for material generation, biopharmaceutical companies can significantly shorten their time to first-in-human (FIH) trials. In this article, CEO and Co-Founder of Wheeler Bio, Inc.'s Jesse McCool and David Schmidt, ATUM's Oren Beske, and Stephen Monks reveals how to the speed of SBC-based platforms to unlock faster pathways to FIH trials. Read the article here: https://lnkd.in/e-ZfX26A
-
-
Willing to explore the use of Raman spectroscopy in your bioprocess but you think it is too complicated and too time consuming: not anymore with this simplified modeling approach.
?? Exciting news from Merck KGaA, Darmstadt, Germany! ?? We are thrilled to announce our latest application note, introducing a new validated methodology designed to streamline the data acquisition modeling phase necessary for Raman spectroscopy implementation in CHO cell culture processes. ?? Discover how this novel methodology can simplify and expedite your Raman implementation and drive forward your bioprocessing capabilities. For more informations, ask an expert here: https://lnkd.in/eEFRsKw9 Let’s innovate and advance together in the journey towards more efficient biopharmaceutical processes! #Biopharma #RamanSpectroscopy #ProcessOptimization #MerckKGaA
-
-
Cellipont Bioservices and Xiogenix Announce Strategic Partnership to Enhance Client Access to Advanced Filling Systems https://lnkd.in/gnbCDMhW THE WOODLANDS, Texas and MUSKEGO, Wis., Dec. 10, 2024 /PRNewswire/ — Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in biopharmaceutical technology, are pleased to announce a [...]
Cellipont Bioservices and Xiogenix Announce Strategic Partnership to Enhance Client Access to Advanced Filling Systems
https://txbn.org
